SLRN实时信号 | 通过Getagraph.com最大化利润

购买 108058 min ago

@ $7.58

发出时间: 14 Feb 2024 @ 23:18

回报率: -42.55%

上一信号: Feb 14 - 01:30

上一信号: 出售

回报率: -1.69 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 00:17):

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines...

Stats
今日成交量	384 917
平均成交量	1.24M
市值	423.91M
EPS	$0 ( 2024-04-02 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.860
ATR14	$0.00700 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-09	Lin Shao-lee	Buy	964 829	Employee Stock Option (right to buy)
2024-01-09	Lin Shao-lee	Buy	413 498	Employee Stock Option (right to buy)
2024-01-09	Labrucherie Gil M	Buy	855 513	Employee Stock Option (right to buy)
2024-01-02	Lin Shao-lee	Sell	10 691	Common Stock
2023-12-18	Tetrault Lynn A.	Buy	89 955	Director Stock Option (right to buy)

INSIDER POWER
-1.39
Last 57 transactions
Buy: 28 627 675 \| Sell: 30 925 812

音量相关性

長: -0.06 (neutral)

短: 0.01 (neutral)

Signal:(49.395) Neutral

Acelyrin, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Acelyrin, Inc. 相关性 - 货币/商品

-0.41
( neutral )

-0.10
( neutral )

0.00
( neutral )

-0.01
( neutral )

0.75
( moderate )

-0.12
( neutral )

Acelyrin, Inc. 财务报表

Annual	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-12.25

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-12.25

Financial Reports:

No articles found.

Acelyrin, Inc.

Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.